Comparative Pharmacology
Head-to-head clinical analysis: JENTADUETO XR versus SITAGLIPTIN AND METFORMIN HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENTADUETO XR versus SITAGLIPTIN AND METFORMIN HCL.
JENTADUETO XR vs SITAGLIPTIN AND METFORMIN HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENTADUETO XR combines linagliptin, a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP) leading to glucose-dependent insulin secretion and decreased glucagon release, and metformin, an AMPK activator that decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), leading to glucose-dependent insulin secretion and decreased glucagon secretion. Metformin is a biguanide that reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
The usual starting dose of JENTADUETO XR (empagliflozin/metformin extended-release) is 5 mg/1000 mg orally once daily with the evening meal. Dose can be increased to a maximum of 12.5 mg/2000 mg once daily based on glycemic control and tolerability.
Initial: 50 mg sitagliptin/500 mg metformin twice daily or 50 mg/1000 mg twice daily (max 100 mg/2000 mg per day). Dose adjusted gradually based on glycemic response and tolerability.
None Documented
None Documented
Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m².
Sitagliptin: terminal t1/2 12.4 hours; Metformin: terminal t1/2 6.2 hours (prolonged to 17.6 hours in renal impairment). Combination: effective t1/2 ~7-12 hours, dosing adjusted for CrCl <45 mL/min.
Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces.
Sitagliptin: 79% excreted unchanged in urine via active tubular secretion and glomerular filtration; 13% metabolized with minimal biliary/fecal elimination (1% unchanged in feces). Metformin: 90% excreted unchanged in urine via active tubular secretion; 0% biliary/fecal.
Category C
Category A/B
DPP-4 Inhibitor / Biguanide Combination
DPP-4 Inhibitor